Next-generation high-affinity three-target eye protein for macular degeneration
Transformational next generation high affinity trispecific fab protein to address unmet needs in Ophthalmology
This project is developing a new three-target antibody fragment to better treat age-related macular degeneration and other retinal diseases caused by abnormal blood vessel growth.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Revopsis Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Springfield, United States) |
| Project ID | NIH-11187102 on NIH RePORTER |
What this research studies
From a patient’s view, researchers are engineering a small three-target protein that can block multiple factors that drive abnormal blood vessel growth and swelling in the back of the eye. The team will make high-affinity versions of this Fab‑type molecule and test how well they bind and neutralize those disease signals in laboratory studies and disease models. The goal is a longer‑lasting therapy that could reduce how often eye injections are needed compared with current anti‑VEGF drugs. If preclinical results are promising, the program would move toward clinical testing in people with wet AMD and related retinal diseases.
Who could benefit from this research
Good fit: Adults with neovascular (wet) age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, or other retinal diseases driven by abnormal blood vessel growth would be the likely candidates for future trials.
Not a fit: People with dry (non‑neovascular) AMD, vision loss from nonvascular causes, or those needing immediate approved treatments are unlikely to benefit from this early-stage development work.
Why it matters
Potential benefit: If successful, the therapy could better preserve vision and reduce the frequency of eye injections for people with neovascular retinal diseases.
How similar studies have performed: Current anti‑VEGF drugs have greatly helped patients but need frequent injections, and multi-target or trispecific biologics are a newer approach that aims to improve durability but remain less tested in humans.
Where this research is happening
Springfield, United States
- Revopsis Therapeutics, INC. — Springfield, United States (Active)
Researchers
- Principal investigator: Xu, Li — Revopsis Therapeutics, INC.
- Study coordinator: Xu, Li
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.